Clinical - REDFILED (Page 2)

Definium is developing an orally disintegrating lysergide tablet for generalized anxiety disorder.

DFTX

DEFINIUM Posts Positive Phase 3 Panorama Data for LSD-Based Anxiety Drug

DT120 ODT cut Hamilton Anxiety scores 5.1 points more than placebo at Week 12, clearing the way for a pre-NDA meeting in 4Q 2026.

AstraZeneca is testing its oral SERD Etcamah across advanced and early breast cancer settings.

AZN

ASTRAZENECA Breast Cancer Trial SERENA-4 Misses Primary Endpoint

AstraZeneca's oral SERD Etcamah plus palbociclib failed to significantly improve progression-free survival in first-line advanced ER-positive breast cancer.

Corbus is developing CRB-913 as an oral, non-incretin treatment for obesity.

CRBP

CORBUS Oral Obesity Pill CRB-913 Shows 5% Weight Loss in Phase 1b

Corbus reported statistically significant weight loss at all three doses of its oral CB1 inverse agonist, with a Phase 2 study planned for the first half of 2027.

IMMP

IMMUTEP Narrows Efti Strategy After TACTI-004 Failure, Blames Manufacturing

Immutep traces the failed TACTI-004 trial to structural differences in efti made at 2,000 L scale and refocuses on HNSCC with CPS < 1 and neoadjuvant sarcoma.

IMNN

IMUNON Signs CRADA With National Cancer Institute for IMNN-001

The NCI's Cancer Therapy Evaluation Program will sponsor and fund new trials of IMUNON's DNA-based IL-12 immunotherapy in additional solid tumors.

An ophthalmologist examines a patient's retina during a clinical eye assessment.

EYPT

EYEPOINT Details LUGANO Miss, Says Nine Patients Drove Failed Endpoint

Expanded Phase 3 data show DURAVYU missed non-inferiority in wet AMD overall but hit it when an asymmetric cohort of nine patients is excluded.

Oral infigratinib is being studied in children with achondroplasia.

BBIO

BRIDGEBIO Says Oral Infigratinib Cut Ear Infections, Stabilized Sleep Apnea

New exploratory PROPEL 3 data show benefits beyond height growth as BridgeBio awaits FDA review of its achondroplasia drug, with a U.S. launch planned for mid-2027.

VERU

VERU Pushes Oral Sabizabulin Into Phase 2 for Daraxonrasib-Resistant Pancreatic Cancer

Veru will seek an FDA pre-IND meeting in Q4 2026 after preclinical data showed sabizabulin remains potent in daraxonrasib-resistant pancreatic cancer cells.

VERU

VERU Pivots Sabizabulin to Pancreatic Cancer After Preclinical Data

Veru will take oral sabizabulin into a planned Phase 2b trial in daraxonrasib-resistant pancreatic cancer and drops its cardiovascular inflammation plan.

GRI Bio's GRI-0621 is being studied in patients with idiopathic pulmonary fibrosis.

GRI

GRI BIO Presents Phase 2a Biomarker Data on GRI-0621 in IPF at ERS 2026

New translational data from the 35-patient Phase 2a study point to a repair phenotype, with placebo-adjusted FVC of +99 mL at Week 12 and no serious drug-related events.

Pharvaris is developing an oral tablet for the prevention of hereditary angioedema attacks.

PHVS

PHARVARIS Phase 3 Prophylaxis Trial Cuts HAE Attacks by 83%

Deucrictibant XR met the primary endpoint and all secondary endpoints in CHAPTER-3, clearing the way for filings starting in the first half of 2027.

Novo Nordisk tested once-weekly semaglutide in children aged 6 to under 12 with obesity.

NVO

NOVO NORDISK Semaglutide Trial in Children Aged 6 to 11 Hits Endpoint

In the STEP Young phase 3 trial, 40.4% of children treated with semaglutide were no longer classified as having obesity after 68 weeks, versus none on placebo.